378 related articles for article (PubMed ID: 23652892)
1. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
Feldman SR; Werner CP; Alió Saenz AB
J Drugs Dermatol; 2013 Apr; 12(4):438-46. PubMed ID: 23652892
[TBL] [Abstract][Full Text] [Related]
2. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
Shalita AR; Berson DS; Thiboutot DM; Leyden JJ; Parizadeh D; Sefton J; Walker PS; Gibson JR;
Clin Ther; 2004 Nov; 26(11):1865-73. PubMed ID: 15639698
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study.
Eichenfield LF; Alió Sáenz AB
J Drugs Dermatol; 2011 Dec; 10(12):1382-96. PubMed ID: 22134562
[TBL] [Abstract][Full Text] [Related]
4. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial.
Leyden JJ; Tanghetti EA; Miller B; Ung M; Berson D; Lee J
Cutis; 2002 Feb; 69(2 Suppl):12-9. PubMed ID: 12095064
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris.
Thiboutot D; Arsonnaud S; Soto P
J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s3-10. PubMed ID: 18575220
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris.
Webster GF; Guenther L; Poulin YP; Solomon BA; Loven K; Lee J
Cutis; 2002 Feb; 69(2 Suppl):4-11. PubMed ID: 12095066
[TBL] [Abstract][Full Text] [Related]
7. Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males.
Cook-Bolden FE; Gold MH; Guenin E
J Drugs Dermatol; 2020 Jan; 19(1):78-85. PubMed ID: 32023013
[TBL] [Abstract][Full Text] [Related]
8. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study.
Leyden J; Thiboutot DM; Shalita AR; Webster G; Washenik K; Strober BE; Shupack J
Arch Dermatol; 2006 May; 142(5):605-12. PubMed ID: 16702498
[TBL] [Abstract][Full Text] [Related]
9. Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials.
Tanghetti EA; Werschler WP; Lain T; Guenin E; Martin G; Pillai R
J Drugs Dermatol; 2020 Jan; 19(1):70-77. PubMed ID: 31985914
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris.
Tanghetti E; Dhawan S; Green L; Del Rosso J; Draelos Z; Leyden J; Shalita A; Glaser DA; Grimes P; Webster G; Barnett P; Le Gall N
J Drugs Dermatol; 2010 May; 9(5):549-58. PubMed ID: 20480800
[TBL] [Abstract][Full Text] [Related]
11. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris.
Pariser D; Colón LE; Johnson LA; Gottschalk RW
J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s18-23. PubMed ID: 18575222
[TBL] [Abstract][Full Text] [Related]
12. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study.
Grimes P; Callender V
Cutis; 2006 Jan; 77(1):45-50. PubMed ID: 16475496
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of topical tazarotene in the treatment of mild to moderate acne.
Leyden JJ
Cutis; 2004 Oct; 74(4 Suppl):9-15. PubMed ID: 15543714
[TBL] [Abstract][Full Text] [Related]
14. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris.
Tanghetti E; Dhawan S; Green L; Ling M; Downie J; Germain MA; Kasteler JS; Kircik L; Oefelein MG; Draelos Z
J Drugs Dermatol; 2011 Jul; 10(7):783-92. PubMed ID: 21720661
[TBL] [Abstract][Full Text] [Related]
15. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial.
Tanghetti E; Abramovits W; Solomon B; Loven K; Shalita A
J Drugs Dermatol; 2006 Mar; 5(3):256-61. PubMed ID: 16573259
[TBL] [Abstract][Full Text] [Related]
16. A status report on topical tazarotene in the management of acne vulgaris.
Del Rosso JQ; Tanghetti E
J Drugs Dermatol; 2013 Mar; 12(3):s53-8. PubMed ID: 23545935
[TBL] [Abstract][Full Text] [Related]
17. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris.
Tanghetti EA; Kircik LH; Green LJ; Guenin E; Harris S; Martin G; Pillai R
J Drugs Dermatol; 2019 Jun; 18(6):542. PubMed ID: 31251546
[TBL] [Abstract][Full Text] [Related]
18. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study.
Shalita AR; Chalker DK; Griffith RF; Herbert AA; Hickman JG; Maloney JM; Miller BH; Tschen EH; Chandraratna RA; Gibson JR; Lew-Kaya DA; Lue JC; Sefton J
Cutis; 1999 Jun; 63(6):349-54. PubMed ID: 10388959
[TBL] [Abstract][Full Text] [Related]
19. Is switching retinoids a sound strategy for the treatment of acne vulgaris?
Gold LS; Colón LE; Johnson LA; Gottschalk RW
J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s11-7. PubMed ID: 18575221
[TBL] [Abstract][Full Text] [Related]
20. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study.
Shalita A; Miller B; Menter A; Abramovits W; Loven K; Kakita L
J Drugs Dermatol; 2005; 4(2):153-8. PubMed ID: 15776771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]